WALTHAM, Mass.--Genome Therapeutics here announced that it acquired an exclusive license to proprietary genes regulated by the T53 tumor suppressor gene from Prince ton University. The agreement will enable Genome Therapeutics to develop proprietary targets within the p53 signal pathway that could lead to the identification of potential gene therapies and the development of new cancer treatments. Under terms of the agreement, Princeton will receive an undisclosed license fee and share in any product royalties created through future alliances.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.